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Mitochondria, the energy reactors of the 
cell, are estimated to contain approxi-
mately 1,500 proteins, but the mito-
chondrial genome itself only encodes 
about 13 of them. The remaining pro-
teins are immigrants that are encoded by 
the nuclear genome. Vamsi Mootha is 
using an integrative 
genomics approach 
to identify all of 
these proteins and 
their functions and 
to understand how 
their mutated ver-
sions lead to disease.
Mootha, who 
built thermodynamic 
models of mito-
chondrial function 
as a medical student (1), honed his genet-
ics skills during his years as a medical resi-
dent and a postdoc (2–5). In addition to 
expanding the database of mitochondrial 
proteins and networks, Mootha, now an 
assistant professor at the Broad Institute 
in Cambridge, MA, is also trying to fig-
ure out why mitochondria are often the 
source of drug toxicity (6).
His team has found that many com-
monly used drugs suppress mitochon-
drial gene expression or interrupt the 
cross-talk between the mitochondrial 
and nuclear genomes. Their discoveries 
help explain many physiological mys-
teries, such as why cholesterol-lowering 
statins cause muscle cramps in some 
users—because they increase the pro-
duction of mitochondrial toxic byprod-
ucts and lower the cell’s energy. 
Mootha, who was awarded the MacArthur 
Foundation’s Genius grant in 2004, 
discussed his ventures into mitochon-
dria in a recent interview.
MATH TO MEDICINE
How did you get interested in science?
I come from a family of physicians. My 
father is a general surgeon and my three 
siblings and their spouses are all physicians. 
So as a child, I wanted to be a physician as 
well. But, in my teens, I became enamored 
by math and computer science. I was 
actually a math geek in high school who 
competed in various math contests.
You pursued your interest in math in 
college. Why did you pick Stanford?
I got into colleges on the East and West 
coasts, and in Texas, which is where I 
grew up. But, being an avid tennis player 
in high school, the weather in Northern 
California and the popularity of tennis 
there made Stanford really appealing to 
me. That, and the fact that math and 
computer science are so strong at Stan-
ford, drew me there.
Did you end up playing tennis for 
Stanford too?
If I could play tennis for Stanford, I 
wouldn’t be talking to you right now. 
I’d be on ESPN.
Fair enough. So how did you go from being 
a mathalete to becoming a med student?
I took a biology class during my junior 
year and absolutely fell in love with 
biochemistry and genetics. And although 
I was good at math, I realized that I 
didn’t have that je ne sais quoi that’s re-
quired to make a fundamentally deep 
impact in mathematics.
So my math advisor strongly urged 
me to think about mathematical biology 
or medicine as a career instead and told 
me about the M.D. program that is 
jointly offered by Harvard/MIT. He 
thought this program would be a fun 
way of entering the research world 
while, at the same time, giving me solid 
training in physiology and teaching me 
about human disease.
What was the program like?
It was small and spectacular. The fi  rst 
two years were heavy with courses that 
were highly quantitative. On the fi  rst 
day of our cardiovascular class, our 
professor said, “Let’s model the heart as 
a thin, massless sphere.” The fi  nal two 
years involved hospital rotations and 
thesis research.
MEETING MITOCHONDRIA
When did you become fascinated with 
mitochondria?
During pathology class in medical 
school, we looked at EM images of a 
patient that had a mitochondrial disorder. 
I remember thinking that these organ-
elles, which had their own DNA and 
evolutionary history, were amazing. And I 
also learned that mutations in mitochon-
drial DNA could give rise to maternally 
inherited disease also got me hooked.
At the end of our second year in 
medical school, some of my friends were 
going to the NIH to do their theses and 
I thought a change of scenery would be 
good for me as well—it was getting 
really cold in Boston. Also, there weren’t 
any labs at Harvard that focused on mito-
chondrial research.
What was your project at the NIH?
I joined the lab of Bob Balaban who was 
working on mitochondrial physiology. 
My job was to build thermodynamic 
models to understand how ATP synthesis 
is regulated.
We made lots of measurements of 
membrane potential, oxygen consump-
tion, ATP production rates, and other 
features that make up the mitochondrial 
circuit and then asked how these processes 
were linked. I guess that our approach 
would be called “systems biology” today, 
but back then it was simply biochemical 
or quantitative physiology.
Combining his medical training with his love of computational biology, 
Mootha is compiling an exhaustive list of mitochondrial genes and networks.
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“I wanted to use 
knowledge of the 
human genome 
to understand 
mitochondrial 
diseases. I was in 
the right place at 
the right time.”
Vamsi Mootha
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MERGING CLINIC WITH LAB
What happened after you got back 
to Boston?
My internship advisor, Jeff   Flier, talked me 
into setting up a physiology rig like the 
one I used at the NIH to study how mito-
chondrial respiration is infl  uenced  by 
factors called uncoupling proteins. These 
are proton channels that disrupt the pro-
ton gradient and prevent it from transmit-
ting the energy needed for ATP synthesis.
And just after I graduated from med-
ical school, Stan Korsmeyer, who had 
discovered the apoptosis gene BCL2 
and its localization in the mitochondria, 
moved his lab to Boston from St. Louis. 
He agreed to let me explore the effect of 
Bcl2 family members on mitochondrial 
physiology, and so I started moonlighting 
in his lab while doing my residency at 
the Brigham and Women’s Hospital.
What did you work on in his lab?
Stan’s lab had previously discovered a 
proapoptotic molecule called Bid that 
somehow triggered cell death when it 
translocated to the outer 
membrane of the mito-
chondria. My work 
showed that Bid was 
puncturing mitochon-
drial membranes and 
causing cytochrome c, 
a member of the elec-
tron transport chain, to 
leak out. This resulted in 
a respiratory block. But adding back   
cyto  chrome c at early time points could 
rescue the respiration.
Did you also get to learn about 
mitochondrial disorders during 
your residency?
Because mitochondrial mutations are so 
rare, I only occasionally got to see patients 
with these disorders, which were mostly 
muscle- or cardiomyopathies. At the 
time, we knew of about 50 mitochon-
drial DNA mutations that had been 
linked to these diseases. But epidemio-
logical studies showed that a majority of 
patients with mitochondrial disease did 
not have mitochondrial DNA mutations. 
I thought that in order to understand 
how mutations in nuclear DNA were 
causing these diseases, we needed to fi  gure 
out the functions of all the proteins in 
the mitochondria.
INTEGRATING DATA
How did you go about your mission?
I was a clinician with a college back-
ground in math and computer science, 
who also had some DNA sequence anal-
ysis experience. It was 2000, I was in 
Boston, and I wanted to use knowledge 
of the human genome to understand 
mito  chondrial diseases. As it turned out, 
I was in the right place at the right time.
You mean because of Eric Lander and the 
Human Genome Project?
Exactly. Eric Lander was leading some of 
the genome sequencing eff  orts right here 
in Cambridge. I joined his lab at the Broad 
Institute as a postdoc right after I fi  nished 
my residency. While brainstorming on 
how to tackle my problem, I heard Mat-
thias Mann give a talk about tandem mass 
spectrometry–based proteomics.
For tandem mass spec, you need two 
things: a sample to analyze 
and a genome sequence 
so that you can figure out 
what your spectra corre-
spond to. So I spent six 
months collecting mito-
chondrial mass spec data 
in Matthias’s lab in Den-
mark. The genome se-
quencing was completed 
just after I got back to Boston and so I 
could start interpreting my mass spec data. 
We found 150 or so new mitochondrial 
proteins this way, which was a big ad-
vance at the time.
Did your expanded database help you 
fi  nd disease-associated genes?
Yes, it did. A genome-wide association 
study had mapped a fatal mitochondrial 
neurodegenerative disease called Leigh 
syndrome to a large chromosome seg-
ment but hadn’t pinpointed the gene. I 
combined the human genetics data with 
our proteomic and genome data to iden-
tify the disease gene, which induces a 
chronic energy shortfall by causing a 
defi  ciency in cytochrome c oxidase—an 
enzyme required for electron transport. 
Our discovery had a big impact: there is 
now a prenatal screening process to pre-
vent parents that are both carriers from 
losing children to the disease.
FUTURE PLANS
What are you working on now?
My lab is using a combination of micros-
copy, mass spectrometry, and computation 
to identify all the component machinery 
of the mitochondria. We’ve clocked about 
1,100 proteins so far. We’ve now mapped 
the evolutionary history of each of these 
proteins and are using this information to 
fi  gure out protein function and identify 
disease genes. We’re also using chemical 
genomics to fi  nd disease biomarkers and 
identify therapeutic strategies.
What’s chemical genomics?
We model these disorders in cell culture 
by using cells from diseased patients or by 
engineering the mutation into normal 
cells. We then screen large collections 
of small molecules or drugs to see if 
any of them suppress or aggravate the dis-
ease phenotype. This approach is helping 
us understand disease pathogenesis and is 
giving us clues for new therapies. My hope 
is that over the next few years, it will help 
us transform mitochondrial medicine.
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Extracts of isolated mitochondria are the 
starting point for Mootha’s protein hunt.
“On the first day of 
our cardiovascular 
class, our professor 
said, ‘Let’s model 
the heart as a thin, 
massless sphere.’”